11月7日,牙科产品制造商登士柏国际(XRAY)盘中大跌超过21%,引发市场强烈关注。股价暴跌的主要原因是公司下调了2024年全年每股收益预期,并暂停了部分产品线的销售。
登士柏国际当天公布,2024年全年每股收益预计为1.82至1.86美元,低于之前预测的1.96至2.02美元。此外,公司自愿暂停了旗下Byte矫正器和印模套件的销售、营销和发货,原因是正在对与之相关的某些监管要求进行审查。
分析人士认为,下调年度利润预期和暂停销售部分产品线,将对登士柏国际今年的收入和利润造成不利影响,引发投资者对公司业绩前景的担忧。尽管第三季度营收高于预期,但似乎并未缓解投资者的忧虑情绪。截至收盘,登士柏国际股价大跌21.93%,至19.41美元,为近24年来新低。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.